BTIG initiated coverage of Graphite Bio (NASDAQ:GRPH) with a “buy” rating and price target of $18. The stock closed at $4.15 on April 13. “We believe Graphite Bio’s homology directed repair technology platform...
BTIG launched coverage of Freeline Therapeutics (NASDAQ:FRLN) with a “buy” rating and price target of $10. The stock closed at $2.37 on Nov. 26. Freeline has built a next-generation gene therapy platform based on a...
BTIG initiated coverage of Mereo Biopharma (NASDAQ:MREO) with a “buy” rating and price target of $10. The stock closed at $3.49 on May 4. “We believe Mereo shares are significantly undervalued with abundant proof-of...
Janney initiated coverage of Applied Genetic Technologies (NASDAQ:AGTC) with a “buy” rating and fair value estimate of $13. The stock closed at $3.20 on Sept. 5. “We see a highly attractive investment opportunity in...